Munich - Delayed Quote EUR

Daiichi Sankyo Co Ltd (D4S.MU)

20.55

+0.35

+(1.73%)

As of 10:34:03 AM GMT+2. Market Open.

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

Clinical Trials Arena 2 days ago

4568.T
+0.85%
AZN
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the DESTINY-Breast09 Phase 3 trial of Enhertu (5.4mg/kg) either alone or in combination with pertuzumab versus standard of care THP (a taxane [docetaxel or paclitaxel], trastuzumab, and pertuzumab) as a first-line treatment in patients with HER2-positive metastatic breast cancer. High-level results from a planned interim analysis showed Enhertu pertuzumab combination demonstrated a statistically significant and clinically meaningf

Benzinga 3 days ago

AZN

4568.T
+0.85%
ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

TOKYO & BASKING RIDGE, N.J., April 21, 2025--ENHERTU Combination Demonstrated Statistically Significant Improvement in PFS vs. THP as First-Line Therapy in HER2 Positive Metastatic Breast Cancer

Business Wire 3 days ago

DSKYF

DSNKY
TAK vs. DSNKY: Which Stock Is the Better Value Option?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 7 days ago

4568.T
+0.85%
TAK
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

The Wall Street Journal 14 days ago

TAK

TKPHF

DSKYF
DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & MUNICH, April 08, 2025--DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.

Business Wire 16 days ago

DSKYF

DSNKY
Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

The approval is supported by the outcomes of the Phase III DESTINYBreast06 trial.

Pharmaceutical Technology 19 days ago

4568.T
+0.85%
AZN
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TOKYO & MUNICH, April 04, 2025--ENHERTU® Approved in the EU as 1st HER2 Directed Therapy for Patients with HR+, HER2 Low or HER2 Ultralow mBC Following at Least 1 Endocrine Therapy

Business Wire 20 days ago

DSKYF

DSNKY
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks 23 days ago

4568.T
+0.85%
TAK
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

TOKYO & BASKING RIDGE, N.J., March 31, 2025--DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

Business Wire 24 days ago

DSKYF

DSNKY
TAK or DSNKY: Which Is the Better Value Stock Right Now?

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Zacks last month

4568.T
+0.85%
TAK
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial

The trial enrolled 494 subjects in Europe, South America, and Asia.

Clinical Trials Arena last month

4568.T
+0.85%
AZN
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

TOKYO & BASKING RIDGE, N.J., March 03, 2025--ENHERTU Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in HER2+ Metastatic Gastric Cancer

Business Wire last month

DSKYF

DSNKY
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TOKYO & MUNICH, February 28, 2025--ENHERTU® Recommended for Approval in the EU by CHMP for HER2 Low or Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Business Wire last month

DSKYF

DSNKY
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo

Ono’s therapy Romvimza is administered twice-weekly compared to Daiichi Sankyo’s twice-daily Turalio.

Pharmaceutical Technology 2 months ago

4568.T
+0.85%
OPHLY
IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says

Northern TK Venture (NTK), a subsidiary of IHH Healthcare, has submitted an expert report by Osborne Partners to a Tokyo court, which states the amount of compensation it is entitled to ranges from 4.24 billion rupees to 109.3 billion rupees, according to a statement on Thursday by its parent. The report includes an analysis and quantification of the damages that NTK suffered based on three scenarios, IHH said.

Reuters 2 months ago

FORTIS.NS

4568.T
+0.85%
Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail

MUNICH & CAMBRIDGE, England, February 04, 2025--Survey reveals: 88% of Western Europeans want better information on breast cancer as misconceptions and lack of awareness prevail

Business Wire 2 months ago

DSKYF

DSNKY
Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

TOKYO & MUNICH, January 31, 2025--Datopotamab deruxtecan (Dato-DXd) has been recommended for approval in the European Union (EU) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.

Business Wire 2 months ago

DSKYF

DSNKY
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO

Okuzawa has been with the company since 1986.

Pharmaceutical Technology 2 months ago

4568.T
+0.85%
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025.

Business Wire 2 months ago

DSKYF

DSNKY

Performance Overview

Return	D4S.MU	Nikkei 225 (^N225)
YTD	-349.71%	-12.17%
1-Year	+357,662.28%	-8.89%
3-Year	+419,310,380.00%	+29.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Daiichi Sankyo Co Ltd (D4S.MU)

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

TAK vs. DSNKY: Which Stock Is the Better Value Option?

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi and AstraZeneca’s Enhertu gains EC approval for breast cancers

ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

TAK vs. DSNKY: Which Stock Should Value Investors Buy Now?

DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer

TAK or DSNKY: Which Is the Better Value Stock Right Now?

Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo

IHH Healthcare's damages against Daiichi could reach $1.25 billion, expert report says

Survey Reveals: 88% of Western Europeans Would Like Better Information on Breast Cancer, Misconceptions and Lack of Awareness of the Disease Still Prevail

Datopotamab Deruxtecan Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer

Performance Overview